New Website Coming! As part of our merger with St. Paul Research, we’re creating a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through their analysts’ additional insight, expertise, and perspective. Be on the lookout for more information in advance of our new website launch on Tuesday, May 18.

Fair Trade

Dear Rundown Reader,

Your opinions on trading school for employment in rural America:

“Doing a work-study type experiment may work but only if there is career growth opportunity and/or financial security as an incentive. 

“Rural areas may have a low cost of living and companies in the area compensate at a lower wage. 

“Unfortunately, the lower re-calibrated compensation means that an under-compensated ‘new-hire’ will have to job hop just to achieve a fair salary level or take on a second job.”

And this…

“In East Tennessee, the trades don’t seem to pay very well.

“In my search for work, I have come across multiple job listings for multi-craft positions. Jobs that require you to hold certificates in welding, hydraulics, and PLC programming but only pay $15.00 an hour.

“Even in our area with the low cost of living, the cost of keeping your certifications up would eat up a good chunk of this small income.”

We appreciate your feedback.

Your Rundown for Thursday, November 15, 2018

Blockbuster

An experimental drug called imlifidase is helping people receive kidney transplants without rejecting the organ.

Swedish pharmaceutical developer Hansa Medical AB “says imlifidase could make transplants possible for about 35,000 U.S. patients who currently have poor odds, and increase matches for others,” Bloomberg reports.

Here’s how the intravenous drug imlifidase works: A lethal bacteria wipes out antibodies that would attack a transplanted kidney. Once the antibodies have a chance to repopulate, the patient is already on immunosuppressants to stave off an autoimmune response.

“Hansa Chief Executive Officer Soren Tulstrup says imlifidase has blockbuster potential, meaning annual sales topping $1 billion,” Bloomberg says.

“The drugmaker plans to file for approval in the U.S. this year or early next. Both U.S. and European Union regulators have granted Hansa eligibility for tax breaks and other incentives for costs of developing treatments for rare conditions.”

If you’d like to invest in Hansa Med, it’s traded on the Nordic Nasdaq. For exposure to the global pharmaceutical market — like Hansa Med — check out VanEck Vectors Pharmaceutical ETF (PPH).

A quick take: The ETF had a 15.22% return in 2017 and 9.74% in 2018.

Market Rundown for Thurs. November 15, 2018

S&P 500 futures are down 18 points to 2,682.31.

Oil is up 41 cents to $56.66.

Gold is up $1.80 to $1,211.90.

Bitcoin’s down $292.94 to $5,447.57.

Have a good day. We’ll talk tomorrow.

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Canary in the Coal Mine

Coming into the day – after a another weekend of surging virus cases – market centers around the world were all in Risk On mode – news that Pfizer and German bio-tech BioNTech were fast tracked by the FDA to produce not one but two virus vaccines for testing apparently sending the algos into overdrive around the world…

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler